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Probiotics are live microorganisms that provide health benefits to the host when they are ingested 
in adequate amounts. The strains most frequently used as probiotics include lactic acid bacteria 
and bifidobacteria. These microorganisms have significant potential as therapeutic options for a 
variety of diseases, but the mechanisms responsible for these effects have not yet been fully 
elucidated. In general, new probiotic strains for human use are sourced from human intestinal flora 
and breast milk. This study sought to survey the existing research regarding the potential for and 
development of technologies regarding infant stool-associated probiotics. The study was performed 
using information from the European Patent Bank, the Bank of the World Intellectual Property 
Organization and the database of the National Institute of Industrial Property of Brazil. The most 
abundant international classification prospected was Subsection C12, particularly class A61N. The 
Republic of Korea has the most patents filed. The results indicate a promising area with significant 
growth in the number of patents. 
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1. Introduction 
According to the Food and Agriculture Organization of the United Nations and the World 
Health Organization (WHO), probiotics are live microorganisms that confer a health benefit to the 
host when they are administered in adequate amounts (FAO/WHO, 2006). Specially, bacteria 
belonging to Bifidobacterium and Lactobacillus, which are the predominant and subdominant 
groups of the gastrointestinal microbiota, respectively, are the most widely used probiotic bacteria 
and are included in many functional foods and dietary supplements (GOURBEYRE et al., 2011). 
Generally, the selection of new probiotic strains for human use is sourced from human intestinal 
flora and breast milk (MARTIN et al., 2009). With a long history of the safe use of probiotics in 
fermented dairy products and growing recognition of their beneficial effects on human health, the 
food industry has become increasingly interested in these types of microorganisms (SHERIDAN et 
al., 2014). Often, the criteria for the selection of probiotics include tolerance to gastrointestinal 
conditions (gastric acid and bile), the ability to adhere to the gastrointestinal mucosa and 
competitive exclusion of pathogens (SANDERS, 2013). The mechanisms underlying the beneficial 
effects of probiotics are largely unknown but are likely to be multifactorial. Several mechanisms 
related to the antagonistic effects of probiotics on various microorganisms include the following: 
secretion of antimicrobial substances, competitive adherence to the mucosa and epithelium, 
strengthening of the gut epithelial barrier, and modulation of the immune system (NEAL-
MCKINNEY et al., 2012; GIORGETTI et al., 2015). 
Probiotic bacteria, both native and those introduced by feeding the host organism, can 
control the initiation and/or development of many pathogenic microorganisms, including 
Salmonella typhymurium, Shigella spp., Clostridium difficile, Campylobacter jejuni and 
Escherichia coli. Probiotics also provide important protection against urogenital pathogens such as 
Gardnerella vaginalis, Candida albicans, and Chlamydia trachomatis (MENARD, 2011). 
Thus, these probiotic strains have been the subject of numerous studies because of an 
increase in the variability of microbial species that have been discovered and tested with potential 
probiotic capabilities. This change has meant that the previous target audience, consisting of elderly 
people, children and adults with poor health, has since expanded to also cover healthy individuals 
and even animals (KORTERINK et al., 2014) 
 Therefore, the accelerated development of scientific knowledge regarding the role of 
probiotics conveyed by dairy products and certain non-dairy products on the health of the host will 
almost certainly result in an expansion of the range of probiotic product options available to 
consumers (ROWLAND et al., 2010). 
 


























Furthermore, consumers are now more aware of probiotics and are increasingly opting for 
products that support a balanced lifestyle, provide health benefits and are attractive from a sensory 
standpoint. Consequently, the market for these products is increasingly competitive. 
The objective of this research is to conduct a survey on patent bases of documents related to 
probiotic products from infants stools, in order to evaluate the panorama of the use of this raw 
material in the elaboration of these products for human health. 
 
2. Methods 
We used the following terms in conjunction with probiotics in the database search: infant 
stools, breast-fed-infant stools, feces of infants, and baby’s stool. The databases used for patent 
research were: INPI - National Institute of Industrial Property; Espacenet - European Patent Office 
(EPO); USPTO - United States Patents and Trademarks Office; and WIPO - Intellectual Property 
Digital Library. The databases used for research papers, theses and dissertations were CAPES 
Periodicals; PubMed; and SCIELO. Initially, the search in the patent databases used the search term 
"probiotic and infant stool”, which resulted in a much lower number of results in the EPO and 
WIPO databases compared with the USPTO database. 
 
3. Results and discussion 
The searches of the patent databases (INPI, EPO, USPTO and WIPO) identified a total of 7 
relevant patents in the WIPO database, 2 patents in the EPO database and 2 patents in the USPTO 
database, as shown in the data presented in Figure 1. No patents were found in the INPI database. 
 








Source: Author's own figure 
 
 


















Year of Filing 
Recently, the INPI has concentrated on using the system of industrial property for more than 
its function of protecting intellectual property. The restructuring work, undertaken since 2004, has 
intended to allow use of the system as a tool of empowerment and competitiveness, which are 
essential to improving countries’ economic and technological development (BARROSO et al., 
2009) 
The documents identified by our searches provided us with the number of relevant patents 
deposited each year. Using the WIPO, which is the most specific patent database (because the 
necessary information to register a patent in the WIPO includes a set of legal references related to 
the patent’s theme of development), we noted that the deposition of patents fluctuated in the past 
decade but remained constant in recent years, although the last year of record is 2014. 
 





   
 
  
              The analysis of the country of origin of each depositor can be observed in Figure 3. The 
Republic of Korea is the largest patent holder, with 5 deposited patents. The United States and 











Source: Author's own figure 
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Brazil does not have any patents in the area of probiotics associated with infant stools. 
perhaps this fact maybe associated with the provisions of Brazilian Law n° 13.123/15 which 
provides for access to genetic heritage, protection and access to associated traditional knowledge, 
and sharing of benefits for the conservation and sustainable use of biodiversity. However it is 
possible to patent genetically modified microorganisms, except for all plants or animals or parts 
thereof (MATTOS; CARDOZO, 2013). In Brazil, the ANVISA, National Sanitary Surveillance 
Agency, which is responsible for certifying the production of food products, decided to exclude the 
list of approved probiotics and defines that the company should propose a functional or health claim 
and it will be evaluated case by case, based on the definitions and principles set out in Resolution 
no. 18/1999. 
At the same time, functional properties and/or health claims on a food label are tools that 
allow the consumer to know the possible benefits the food can offer. However, it is necessary to 
clearer rules for the industry so that the consumer is not deceived by false cure promises 
(SILVEIRA et al., 2009) 
Among the documents identified in the survey, 55% are related to the field of 
microorganisms or enzymes and their compositions (C12N); 18% are in the area of food, food 
products and non-alcoholic beverages and preparations for medical purposes (A61K and A23C, 

























As proposed by Vasconcellos et al. (2001), the subclass C12N was used as most 
representative of modern biotechnology, as it encompasses the technologies related to 
"Microorganisms or enzymes; their compositions; propagation, preservation or maintenance of 
micro-organisms or tissues; genetic engineering or mutation; culture mediums". Significant 
advances in the area of biotechnology in Brazil came mainly with the approval of Law No. 9279/96, 
which controls industrial property rights and obligations. 
A61K (preparations for medical, dental or hygienic purposes) and A23C which is part of 
Section A - for human needs, linked to class 23 related to food or food products; not covered by 
other classes and subclass C dairy products, ex. milk, butter, cheese; substitutes for milk or cheese; 
important feature associated mainly with products with probiotic purposes. 
Among the probiotics, the genera Bifidobacterium and Lactobacillus stand out 
(VARAVALLO et al., 2008), in particular, the species Lactobacillus acidophilus (THAMER; 
PENNA, 2005). These genera are present in yogurts, fermented dairy products and dietary 
supplements (RAIZEL et al., 2011). Enterococcus faecium are also employed, but on a smaller 
scale, in addition to other lactic acid bacteria, non-lactic acid bacteria and yeasts (PROBIOTICS, 
[2010?]). 
The search on patent databases and scientific production identified 17,166 documents in 
PubMed (US National Library of Medicine), 596 scientific papers in the Scielo (Scientific 




Source: Author's own figure 
 
 



































































































Table 1. Number of research papers, theses and dissertations from keyword searches in different databases 
Keyword CAPES PubMed SCIELO 
Probiotic* 15,478 16,682 573 
Probiotic* and (breast-fed-infant stools OR infant 
feces OR baby's stool) 130 324 21 
Food* and probiotic* and (breast-fed-infant stools 
OR infant feces OR baby’s stool) 
37 147 1 
Probiotic* and Product* and (breast-fed-infant stools 
OR infant feces OR baby's stool) 
27 13 1 
Total 15,672 17,166 596 
 
With the search keywords and associations using Boolean operators outlined in Table 1, the 
largest volume of documents was found with the PubMed search. This is because PubMed is the 
search engine for the MEDLINE database of references and abstracts, and MEDLINE is the largest 
medical and natural sciences database in the world. 
According to the analysis of the articles extracted from MEDLINE by year, the annual 
production of work related to probiotics and associated with the word "infant stool” was scarce until 
the end of the 1990s and fluctuated greatly in the 2000s, with the highest number of publications in 
2014. The number of scientific papers found was much higher than the number of patents in the 
WIPO database (Figure 5). 
 











Source: Author's own figure 
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4. Conclusions 
 The Republic of Korea has largest number of patent applications in this area, followed by the 
United States and Japan. Brazilian legislation is not clear as to the use of probiotics, since in the 
market are found foods considered probiotics, and often used as medicines. Although, several 
scientific projects specifically in the area of probiotics has grown tremendously in recent years. The 
public expects future innovations to produce more diverse probiotic products aimed at contributing 
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